HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wellness Market News: Formula Fails Standards, CarnoSyn Trademark Infringement Alleged, More

Executive Summary

Former FDA chief Kessler heads CSPI board; CRN-supported Rose Awards go to Ross, Das; Bobbie Baby infant formula fails FDA standards; CRN launches Retailer Relations Forum; and NAI alleges CarnoSyn trademark infringement by Vitalize.

You may also be interested in...



Else Nutrition Takes 'Clean Label' Into Infant Formula, Toddler Beverage Market

Else Nutrition will be one of the first companies to market baby and toddler formula and a children’s beverage without dairy or soy while containing a few core ingredients, says CEO Hamutal Yitzhak. Products will debut in North America and Europe in 2020.

UK OTC Industry Association Elects Haleon’s Bas Vorsteveld As President

Haleon’s UK and Ireland general manager Bas Vorsteveld becomes PAGB president, replacing Perrigo's Neil Lister. Lister reflects on a turbulent four years chairing the UK industry association. 

Countries To Discuss Pandemic Treaty Next Year Amid Industry Concern

A World Health Organization negotiating body has agreed to develop a “zero draft” of the proposed pandemic treaty for discussion at a meeting of WHO member states in February next year. But the international pharmaceutical industry has reiterated its concerns about some of the proposals being put forward.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS148898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel